CJC-1295 / Ipamorelin: What It Is and Its U.S. Regulatory Status

What is a CJC-1295 / ipamorelin blend?

This name describes a combination of two separate synthetic peptides. CJC-1295 is a modified analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor. Both act on the pituitary gland, but through different receptors.

The blend is a marketing combination, not a product that has been developed and tested as a single drug. Each peptide has its own profile in our Peptide Guide.

U.S. regulatory status

Current status: Not FDA-approved.

In practical terms, this blend has not gone through the FDA review that a drug must pass before it can be marketed for use in people. There is no FDA-approved product that contains it.

Neither CJC-1295 nor ipamorelin is FDA-approved on its own, and no combination of the two has been approved. Both are prohibited in competitive sport under the World Anti-Doping Code.

Why Peptide Labs does not sell this blend

Peptide Labs does not sell this compound. This page is general information, not medical advice. We do not supply this blend, and we do not point readers to anyone who does.

For personal medical questions, including questions about this blend, the right person to ask is a licensed healthcare provider.

Related reading

See the full list of compound profiles in the Peptide Guide.